pfizer-biontech booster (bnt162b2  (BioNTech)

Journal: Infection Prevention in Practice

Article Title: Prevalence of side‐effects associated with the booster dose of Pfizer-BioNTech (BNT162b2) of COVID-19 Vaccine among vaccinated adults in the Eastern province of Saudi Arabia

doi: 10.1016/j.infpip.2022.100251

Figure Lengend Snippet: Total number of COVID‐19 vaccine side‐effects reported among the participants associated with COVID-19 Booster dose-vaccine of Pfizer-BioNTech (BNT162b2) among respondents.

Article Snippet: Total number of COVID‐19 vaccine side‐effects reported among the participants associated with COVID-19 Booster dose-vaccine of Pfizer-BioNTech (BNT162b2) among respondents.

Techniques:

Journal: Infection Prevention in Practice

Article Title: Prevalence of side‐effects associated with the booster dose of Pfizer-BioNTech (BNT162b2) of COVID-19 Vaccine among vaccinated adults in the Eastern province of Saudi Arabia

doi: 10.1016/j.infpip.2022.100251

Figure Lengend Snippet: Frequency and types of side‐effects associated with COVID-19 Vaccines among respondents.

Article Snippet: Total number of COVID‐19 vaccine side‐effects reported among the participants associated with COVID-19 Booster dose-vaccine of Pfizer-BioNTech (BNT162b2) among respondents.

Techniques:

Journal: Frontiers in Neurology

Article Title: Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases

doi: 10.3389/fneur.2021.765954

Figure Lengend Snippet: New MRI lesions associated with the MS episodes occurred after ChAdOx1 nCoV-19 (AZD12222), mRNA-1273, Moderna and BNT162b2, Pfizer/BioNTech vaccine. The lesions are shown on T2 weighted images or on post-contrast T1 weighted images and are indicated by yellow arrows. (A) Case 1: C3 lesion; (B) Case 2: new enhancing lesion in corpus callosum and multiple white matter unenhanced lesions in periventricular areas and in the mesial occipital lobe; (C) Case 3: new enhancing lesion in the thoracic cord; (D) Case 4: multiple hyperintense lesions in the supra and infratentorial white matter, four of which are with contrast enhancement; (E) Case 5: new brain lesion with contrast enhancement. (F) Case 6: enhancing bulbar lesion; (G) Case 7: C3 lesion with contrast enhancement; (H) Case 8: new brain enhancing lesion; (I) Case 9: a new contrast enhancing lesion in the mesencephalon. (L) Case 10: new enhancing brain lesion. (M) Case 11: enhancing brain lesion with conspicuous oedema; (N) Case 12: a new active lesion with ring enhancement in the left frontal white matter. (O) Case 13: three new brain enhancing lesions, one of which is indicated by the arrow; (P) Case 14: three new enhancing lesions in the left temporal lobe and one, indicated here, in the left centrum semiovale; (Q) Case 15: two ring-enhancing lesions localized in the white matter adjacent to the left frontal horn and in the left middle periventricular region. (R) . Case 16: new enhancing lesions, one of which is tumefactive, localized in the white matter of the left centrum semiovale.

Article Snippet: He received the BNT162b2/Pfizer-BioNTech booster on May 11, 2021. without any further medical problem.

Techniques: